To investigate the absorption and metabolism of an anti carcinogenic tea catechin, (-)-epigallocatechin-3-gallate (EGCg), in rats, a newly developed chemiluminescence-detection high-performance liq uid chromatography (CL-HPLC) method was employed and the EGCg concentrations in blood plasma, liver, brain, small intestinal mucosa and colon mucosa were determined before and after EGCg administration. The recovery of EGCg, extracted consecutively with ethyl acetate and methanol, was 86.1% from plasma and 64.5-74.2% from the tissue samples. The EGCg concentrations of plasma and tissue samples from the control rat (before EGCg administration) were all below the detection limit (<0.002 nmol/mL, 0.002 nmol/g), but 60 min after a single oral administration of EGCg (500mg/kg body weight), the levels increased, reaching 12.3nmol/mL in plasma, 48.4nmol/g in liver, 0.5nmol/g in brain, 565nmol/g in small intestinal mucosa and 68.6nmol/g in colon mucosa. The EGCg levels found in the tissues corresponded to 0.0003-0.45% of ingested EGCg. The results indicate that tea catechin, EGCg, is absorbed from the digestive tract, with the intestinal mucosa the most enriched of the organelles. This may explain the potent antioxidant function of EGCg in inhibiting colon mucosal phospholipid hydroperoxidation in the prevention of rat colonic carcinogenesis.
(-)-Epigallocatechin-3-gallate (EGCg) is a tea catechin and is consumed as a popular beverage in Japan and other Asian countries. In recent years, several epidemiologic studies have suggested a lower risk of gastric cancer for green tea drinkers (1) .
Several tea catechins have been reported to act as water-soluble antioxidants in vitro by scavenging oxygen radicals, chelating metal ions, and inhibiting lipoxy * To whom correspondence should be addressed .
genase (2) . If EGCg in free form could be efficiently incorporated into the tissue organelles, its antioxidant activity may provide a beneficial anti-carcinogenic effect in cases involving membrane phospholipid peroxidation, such as the development of colon cancer (3) . The incorporation of EGCg into the tissue organelles of mammals except for body fluids such as plasma and urine has never been confirmed . It is therefore of interest to examine whether EGCg orally ingested is absorbed and incorporated directly in free form into intestinal mucosa, liver and other tissues .
In this study, we employed a chemiluminescence-detection high-performance liquid chromatography (CL-HPLC) method (4) which was recently established to determine EGCg in biological fluids, and confirmed the absorption and distribution of EGCg in free form into rat tissues. 
Discussion
The occurrence of tea catechins, especially of EGCg, in body fluids has been reported (5-7), but not in the tissue organelles. This study demonstrated the incorporation of EGCg in free form into the liver, brain, small intestinal mucosa and colon mucosa of the rat after EGCg ingestion. Relatively high levels of EGCg were detected in alimentary tract tissues such as the small intestinal mucosa and colon mucosa (Table 2 ). This may mean that the intestines are the major absorption site of EGCg in mammals. This data also indicates that EGCg is transportable in small amounts to the most conservative organ, the brain.
Liver and intestinal walls contain enzymes which would be responsible for the conjugation and methylation of EGCg (i.e., UDP-glucuronosyl transferase and catechol-O-methyl transferase). Intestinal microorganisms contain certain enzymes involved in the ring-fission of EGCg (8) . In this study, two unknown minor chemiluminescence peaks, speculated to be the metabolites of EGCg, were observed in the liver of rats at 60min after EGCg intake. On the other hand, only EGCg in free form was found as the major chemiluminescence peak in both small intestinal mucosa and colon mucosa. The EGCg incorporated into the blood stream could be transported to the tissue organelles as discussed by Hackett (9) . The EGCg could also be excreted into bile from the liver. On the other hand, as a result of biliary excretion, EGCg could be excreted into the duodenum. It is probable that some EGCg would then be further reabsorbed from the intestines to the liver thus creating an enterohepatic circulation system as has been suggested to occur in the rat (9) .
As metabolites of EGCg, Lee et al (5) reported that the glucuronide and sulfate of EGCg appear in human plasma after the ingestion of green tea extract . Hackett (9) has found (+)-catechin in the form of methylate, glucuronide and sulfate in plasma, urine and bile after its administration to rats. Oshima and Watanabe (10) reported that the oral administration of (+)-catechin to rabbit results in the ex cretion of its ring-fission product in urine. Also for 3-O-methyl-(+)-catechin and flavonoid (7-mono-O-(fl-hydroxyethyl) rutin), the glucuronide conjugates have been found in the urine and plasma of mammals (9) . Thus some degree of conjugation , methylation and ring-fission reaction seem to be involved in EGCg metabolism .
In terms of the possible therapeutic use of EGCg against digestive cancer, we recently reported that green tea extract, mainly consisting of EGCg , clearly prevents 1, 2-dimethylhydrazine-induced colonic carcinogenesis in rats, in which the levels of phospholipid hydroperoxide as a peroxidized membrane lipid marker were significantly and dose-dependently lowered in colon mucosal cells as compared to the control rats (3). This directly indicated at first that the potent antioxidant function of EGCg is involved essentially in the prevention of colonic carcinogenesis. As the antioxidant mechanisms, metal chelation, hydrogen donation, lipoxygenase inhibition and reactive oxygen elimination would be responsible. As shown here, since relatively high concentrations of EGCg were found in the intestinal mucosa in the EGCg-supplemented rats, the ingestion of EGCg as an antioxidative nutrient to prevent intestinal carcinogenesis may be recommendable. The findings presented here help to explain the anticarcinogenic properties of green tea as revealed in several epidemiological studies (1).
The gift of pure green tea EGCg from Taiyo Kagaku (Yokkaichi, Japan) is gratefully acknowledged. We thank Dr. H. Matsumoto (Kyoto Prefectural University of Medicine) for his valuable technical comments for the mucosal sample preparation.
